Physician profile
Mark Robert Mc Laughlin
NPI 1053382366
$1,170.41
in general payments reported to CMS, 2019-2025
16 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.82 · 2020: $29.86 · 2021: $244 · 2022: $438 · 2023: $35.85 · 2024: $24.98 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $231.21 | 2022-2025 | General - Therapies |
| Nevro Corp. | $142.07 | 2022-2023 | Senza |
| Microtransponder, INC. | $116.87 | 2025 | |
| Intrinsic Therapeutics | $114.73 | 2022 | |
| Spine Wave, INC. | $112.23 | 2021 | |
| Medtronic, INC. | $89.53 | 2022 | |
| Si-Bone, INC. | $81.28 | 2021 | |
| Stryker Corporation | $66.61 | 2020-2022 | |
| Orthofix Medical, INC. | $50.59 | 2021 | |
| Alphatec Spine, INC | $42.43 | 2025 | Other - Miscellaneous |
| Nuvasive, INC. | $30.36 | 2019 | |
| Baxter Healthcare | $27.99 | 2019 | |
| Abbott Laboratories | $24.98 | 2024 | Proclaim |
| Portola Pharmaceuticals, LLC | $14.24 | 2019 | |
| Ethicon US, LLC | $13.06 | 2023 | Echelon; Endopath |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$400.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mc Laughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.